- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00895024
Caregiver Assessments of the Quality of Home Hospice Care
Caregiver Assessments of the Quality of Home Hospice Care: A Comparison Across 3 Ethnic Groups (A Preliminary Study)
The Objectives are to administer the Family Evaluation of Hospice Care (FEHC) questionnaire and The Texas Revised Inventory of Grief (TRIG) to caregivers previously enrolled into the parent grant and conduct supplemental analyses to:
- examine cross-ethnic differences in the caregivers' quality of hospice care assessments.
- investigate the association between parenteral hydration status of the patient and the quality of care assessments provided by the caregivers after death.
- examine the association between levels of grief (as measured by the TRIG) and the quality of hospice care assessments provided by the caregiver.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
After the death of their loved-ones, caregivers will be asked to report on the care received by their care recipient and the quality of practical and emotional care provided to them by hospice by completing the 25-minute FEHC questionnaire over the phone. Caregivers will also be asked 16 additional questions to assess their attitudes and beliefs about hydration at the end of life, and a brief questionnaire to assess past and current levels of grief (TRIG). The additional questions on hydration and grief can easily be completed in less than 10 minutes over the phone. The entire interview should take no more than 35 minutes to complete.
Bereaved caregivers who have participated in the parent grant and have lost their loved one within 3-23 months will be mailed a letter from Drs. Bruera and Torres inviting them to participate in the voluntary supplemental after-death survey. The letter will include a brief description of the research study and appropriate contact information for the caregiver to call if she/he is interested in participating. The letters then will be followed up by a phone call from Dr. Torres to verify receipt of the letter. If the caregivers express their interest in participating in the study, they will be asked a few screening questions over the phone to verify their eligibility. Once found eligible for the study, a telephone verbal consent will be obtained.
Dr. Isabel Torres will conduct the phone interviews with 128 primary caregivers who had previously completed the parent grant protocol.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Bereaved family caregivers who completed their participation in the parent protocol (2006-0494) and have lost their loved one within 3-23 months.
- Caregivers who participated in the parent grant met the inclusion/exclusion criteria of the parent grant.
Exclusion Criteria:
- Bereaved family caregivers who did not complete their participation in the parent protocol or any other caregiver who was never enrolled in the parent protocol (2006-0494).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Caregivers
|
35-minute questionnaire over the phone.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Survey assessment of cross-ethnic differences in caregivers' quality of hospice care
Time Frame: 3-23 Months After Hospice Care
|
3-23 Months After Hospice Care
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lorna H. McNeill, MPH, PHD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2009-0031
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancer
-
STORM Therapeutics LTDRecruitingCancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Merck Sharp & Dohme LLCCompletedAdvanced Cancer Relapsed | Advanced Cancer Refractory
-
Teon Therapeutics, Inc.Merck Sharp & Dohme LLCTerminatedCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
BiOneCure Therapeutics Inc.RecruitingCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
PfizerTerminatedAdvanced Solid Tumors | Advanced CancerUnited States
-
Avera McKennan Hospital & University Health CenterCompleted
-
AVEO Pharmaceuticals, Inc.CompletedAdvanced Cancer | Refractory CancerUnited States
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...RecruitingAdvanced CancerItaly
-
Suzhou Transcenta Therapeutics Co., Ltd.Bristol-Myers SquibbRecruiting
Clinical Trials on Phone Interview/Questionnaire
-
M.D. Anderson Cancer CenterNational Institute of Dental and Craniofacial Research (NIDCR); American Cancer...Unknown
-
Medical University of ViennaRecruitingExtracorporeal Membrane Oxygenation | ARDS | COVID-19 PneumoniaAustria
-
Wei DaiInternational Headache SocietyRecruitingMigraine Disorders | Medication-overuse HeadacheChina
-
University of SienaRecruiting
-
National Taiwan University HospitalCompletedIntra Cerebral HemorrhageTaiwan
-
University Hospital, ToulouseNot yet recruitingPrader-Willi SyndromeFrance
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)Completed
-
Papa Giovanni XXIII HospitalGENOSCompletedCovid19 | Chronic Pain | Morbidity, MultipleItaly
-
Northwestern UniversityRegeneron PharmaceuticalsCompletedPsoriasis | Atopic Dermatitis | IchthyosisUnited States
-
Central Hospital, Nancy, FranceCompletedDisease | Child Development | Denial (Psychology) | Personality DevelopmentFrance